Chronic Stable Angina
Conditions
Interventions
the treatment group:Wufuxinnaoqing Soft Capsule
Control:Placebo
Sponsors
China Xiyuan Hospital of China Academy of Chinese Medical Sciences
Eligibility
Sex/Gender
All
Age
34 Years to 71 Years
Inclusion criteria
Inclusion criteria: 1. To be met any of following diagnostic standard of coronary heart disease: (1) with a clear history of old myocardial infarction, or history of PCI, or history of bypass; (2) coronary angiography results suggested that at least one coronary artery was stenosed and the stenosis was more than 50% or coronary CTA suggested a stenosis of more than 50%; (3) diagnosed of myocardial ischemia of coronary artery disease by radionuclide; (4) submaximal exercise treadmill ECG test was positive; (5) angina attacks with typical ischemic ECG; 2. Patients to be complicated with blood stasis syndrome differentiation criteria in Chinese medicine; 3. meeting the diagnostic criteria for chronic stable angina, with a history of angina pectoris longer than 1 month; 4. attacks of angina more than 2 times/week and less than 5 times/day; 5. CCS angina classification grade I-III; 6. continuous use of the current drugs for treatment of angina for a month or more; 7. between the ages of 30 to 70 years; 8. research program approved by each member of ethics committee and signed the clinical research ethic documents.Patients were informed, and voluntarily signed the informed consent; 9. at the end of the import period meeting the above standards.
Exclusion criteria
Exclusion criteria: 1. with severe heart diseases (unstable angina, acute myocardial infarction occurred within six months, etc), severe cardiopulmonary dysfunction (heart function grade III or IV, severe lung abnormalities); 2. with hypertension beyond control (systolic blood pressure higher than 160mmHg or diastolic blood pressure higher than 100mmHg after treatment); 3. combining severe liver and kidney dysfunction, combining severe primary diseases such as hematopoietic system diseases, or combining mental diseases; 4. within three months after the intervention; 5. patients who had regularly used beta-blockers in past month and could not stop the drugs by the judgment of researchers; 6. patients with pacemakers; 7. during pregnancy, lactation or pregnancy planner; 8. patients who had participated in other clinical researches within the past three months; 9. allergies or known allergy to the experimental drug; 10. people who researchers believed should not participate in clinical research.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Angina symptom score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Quantified score of Chinese medicine syndrome; | — |
Countries
China
Contacts
Public ContactXU Feng-qin
Outcome results
None listed